Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.: TR-FRET to quantify HER dimers and evaluate mAb efficiency

Abstract : In oncology, simultaneous inhibition of epidermal growth factor receptor (EGFR) and HER2 by monoclonal antibodies (mAbs) is an efficient therapeutic strategy but the underlying mechanisms are not fully understood. Here, we describe a time-resolved fluorescence resonance energy transfer (TR-FRET) method to quantify EGFR/HER2 heterodimers on cell surface to shed some light on the mechanism of such therapies. First, we tested this antibody-based TR-FRET assay in NIH/3T3 cell lines that express EGFR and/or HER2 and in various tumor cell lines. Then, we used the antibody-based TR-FRET assay to evaluate in vitro the effect of different targeted therapies on EGFR/HER2 heterodimers in the ovarian carcinoma cell line SKOV-3. A simultaneous incubation with Cetuximab (anti-EGFR) and Trastuzumab (anti-HER2) disturbed EGFR/HER2 heterodimers resulting in a 72% reduction. Cetuximab, Trastuzumab or Pertuzumab (anti-HER2) alone induced a 48, 44, or 24% reduction, respectively. In contrast, the tyrosine kinase inhibitors Erlotinib and Lapatinib had very little effect on EGFR/HER2 dimers concentration. In vivo, the combination of Cetuximab and Trastuzumab showed a better therapeutic effect (median survival and percentage of tumor-free mice) than the single mAbs. These results suggest a correlation between the extent of the mAb-induced EGFR/HER2 heterodimer reduction and the efficacy of such mAbs in targeted therapies. In conclusion, quantifying EGFR/HER2 heterodimers using our antibody-based TR-FRET assay may represent a useful method to predict the efficacy and explain the mechanisms of action of therapeutic mAbs, in addition to other commonly used techniques that focus on antibody-dependent cellular cytotoxicity, phosphorylation, and cell proliferation.
Type de document :
Article dans une revue
Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, 2011, 286 (13), pp.11337-45. 〈10.1074/jbc.M111.223503〉
Liste complète des métadonnées

Littérature citée [42 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00576598
Contributeur : Yves Le Ster <>
Soumis le : mardi 31 janvier 2012 - 17:39:05
Dernière modification le : mercredi 3 octobre 2018 - 16:02:08
Document(s) archivé(s) le : mardi 1 mai 2012 - 02:20:38

Fichiers

110118def3_publiNG.pdf
Fichiers produits par l'(les) auteur(s)

Identifiants

Citation

Nadège Gaborit, Christel Larbouret, Julie Vallaghe, Frédéric Peyrusson, Caroline Bascoul-Mollevi, et al.. Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.: TR-FRET to quantify HER dimers and evaluate mAb efficiency. Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, 2011, 286 (13), pp.11337-45. 〈10.1074/jbc.M111.223503〉. 〈inserm-00576598〉

Partager

Métriques

Consultations de la notice

348

Téléchargements de fichiers

633